Q-omics provides the consensus-scored ZNF10 profile across patient tissues and cancer cell-line models. ZNF10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF10 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ZNF10 RNA expression shows 21,254 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where ZNF10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF10 survival associations across molecular data types. ZNF10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF10 RNA expression–survival associations across cancer types. High ZNF10 expression shows unfavorable associations in KIRC, but favorable associations in HNSC, UCS, LUAD, PAAD and GBM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF10 RNA expression.
This table summarizes ZNF10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF10 shows lower tumor expression in KIRC, KICH, THCA, BRCA and BLCA and higher tumor expression in LIHC. The KIRC box plot shows higher ZNF10 RNA expression in normal versus tumor tissue (log2 FC = −0.758, t-test p < 0.001).
This table shows molecular features associated with ZNF10 in patient tissues and cancer cell lines. In patient samples, ZNF10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
